litlas
ログインアカウント作成

Ana Arance

2000–2025 年に発表

121
論文数
35,751
被引用数
62
h 指数
103
i10 指数

被引用数

Ana Arance の年別被引用数2001 年: 被引用 4 件2002 年: 被引用 1 件2003 年: 被引用 1 件2004 年: 被引用 6 件2005 年: 被引用 9 件2006 年: 被引用 2 件2007 年: 被引用 6 件2008 年: 被引用 3 件2009 年: 被引用 2 件2010 年: 被引用 6 件2011 年: 被引用 1 件2012 年: 被引用 1 件2013 年: 被引用 6 件2014 年: 被引用 31 件2015 年: 被引用 251 件2016 年: 被引用 543 件2017 年: 被引用 642 件2018 年: 被引用 694 件2019 年: 被引用 1,983 件2020 年: 被引用 2,153 件2021 年: 被引用 2,027 件2022 年: 被引用 1,806 件2023 年: 被引用 1,338 件2024 年: 被引用 2,147 件2025 年: 被引用 949 件2026 年: 被引用 23 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,947 件、この内訳の 24.4%中国: 引用元論文 1,805 件、この内訳の 11.1%ドイツ: 引用元論文 990 件、この内訳の 6.1%イタリア: 引用元論文 989 件、この内訳の 6.1%フランス: 引用元論文 883 件、この内訳の 5.5%イギリス: 引用元論文 825 件、この内訳の 5.1%オーストラリア: 引用元論文 713 件、この内訳の 4.4%スペイン: 引用元論文 554 件、この内訳の 3.4%オランダ: 引用元論文 551 件、この内訳の 3.4%日本: 引用元論文 506 件、この内訳の 3.1%カナダ: 引用元論文 470 件、この内訳の 2.9%スイス: 引用元論文 466 件、この内訳の 2.9%
0%24.4%その他 21.6%

機関

分野

  • Medicine66.1%
  • Biochemistry, Genetics and Molecular Biology21.3%
  • Immunology and Microbiology7.2%
  • Neuroscience2.1%
  • Engineering1%
  • Computer Science0.6%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers18.2%
  • Immunotherapy and Immune Responses7.2%
  • Melanoma and MAPK Pathways6.5%
  • CAR-T cell therapy research6.3%
  • Cutaneous Melanoma Detection and Management4.7%
  • Immune Cell Function and Interaction3%
  • その他54.1%

共著者

全論文

検索で開く
  1. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

    著者: Hussein A. Tawbi, Dirk Schadendorf, Evan J. Lipson, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Shivani Srivastava, Mena Abaskharoun, Melissa Hamilton, Sarah Keidel, Katy L. Simonsen, Anne Marie Sobiesk, Bin Li, F. Stephen Hodi, Georgina V. Long - New England Journal of Medicine 2022 被引用: 1,759

  2. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    著者: Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas - New England Journal of Medicine 2015 被引用: 5,847

  3. Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    著者: Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Ana Arance, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, L. Lundgren-Eriksson, Christine E. Horak, Brian J. Sharkey, Ian M. Waxman, Victoria Atkinson, Paolo A. Ascierto - New England Journal of Medicine 2014 被引用: 5,352

  4. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

    著者: Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas F. Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean‐Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R. Anderson, Janet Maleski, Mark M. Jones, Scott J. Diede, Tara C. Mitchell - The Lancet Oncology 2019 被引用: 944

  5. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    著者: Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto - New England Journal of Medicine 2017 被引用: 2,207

  6. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    著者: Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V. Long - The Lancet Oncology 2019 被引用: 1,153

  7. Clinical implications of the intrinsic molecular subtypes of breast cancer

    著者: Aleix Prat, Estela Pineda, Bárbara Adamo, Patricia Galván, Aranzazu Fernández-Martínez, Lydia Gaba, Marc Díez, Margarita Viladot, Ana Arance, Montserrat Muñoz-Mateu - The Breast 2015 被引用: 1,310

  8. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    著者: Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty - The Lancet Oncology 2018 被引用: 1,016

  9. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    著者: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymyr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, Michelle Casey, Danièle Ouellet, Anne‐Marie Martin, Ngocdiep T. Le, Kiran Patel, Keith T. Flaherty - New England Journal of Medicine 2014 被引用: 1,871

  10. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    著者: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert - The Lancet 2017 被引用: 1,239

  11. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    著者: Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Célèste Lebbé, Hildur Helgadóttir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio Maria Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion‐Sileni - Journal of Clinical Oncology 2022 被引用: 220

  12. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

    著者: Michael A. Davies, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Keith T. Flaherty, Ana Arance, Vanna Chiarion‐Sileni, L. Thomas, Thierry Lesimple, Laurent Mortier, Stergios J. Moschos, David Hogg, Iván Márquez‐Rodas, Michele Del Vecchio, Célèste Lebbé, Nicolás Meyer, Ying Zhang, Yingjie Huang, Bijoyesh Mookerjee, Georgina V. Long - The Lancet Oncology 2017 被引用: 775

  13. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

    著者: Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber - The Lancet Oncology 2020 被引用: 525

  14. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    著者: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, S. Swann, Jeffrey J. Legos, Fan Jin, Bijoyesh Mookerjee, Keith T. Flaherty - The Lancet 2015 被引用: 1,386

  15. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

    著者: James Larkin, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey S. Weber - Clinical Cancer Research 2023 被引用: 180

  16. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

    著者: Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi - NEJM Evidence 2023 被引用: 124

  17. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithBRAFV600–Mutant Melanoma

    著者: Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo A. Ascierto - Journal of Clinical Oncology 2022 被引用: 185

  18. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

    著者: Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Iván Márquez‐Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, Andrew Mant, Muhammad A. Khattak, Catalin Mihalcioiu, Sekwon Jang, C. Lance Cowey, Alan D. Smith, Natalyn Hawk, Ke Chen, Scott J. Diede, Clemens Krepler, Georgina V. Long - Journal of Clinical Oncology 2022 被引用: 127

  19. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600–Mutant Unresectable or Metastatic Melanoma

    著者: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - Journal of Clinical Oncology 2022 被引用: 163

  20. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

    著者: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul Nathan, Piotr Rutkowski, О. В. Леонов, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean‐Jacques Grob, Nicolás Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steve Green, T Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - 2022 被引用: 146

  21. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

    著者: Caroline Robert, Matteo S. Carlino, Catriona M. McNeil, Antoni Ribas, Jean‐Jacques Grob, Jacob Schachter, Marta Nyakas, Damien Kee, Teresa M. Petrella, Arnold Blaustein, Michal Lotem, Ana Arance, Adil Daud, Omid Hamid, James Larkin, James R. Anderson, Clemens Krepler, Dmitri Grebennik, Georgina V. Long - Journal of Clinical Oncology 2023 被引用: 113

  22. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

    著者: G.V. Long, K.T. Flaherty, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, Vanna Chiarion‐Sileni, C. Lebbe, M. Mandalá, M. Millward, Ana Arance, Igor Bondarenko, J.B.A.G. Haanen, J. Hansson, Jochen Utikal, Virginia Ferraresi, P. Mohr, V. Probachai, Dirk Schadendorf, Paul Nathan, C. Robert, A. Ribas, M.A. Davies, S.R. Lane, J.J. Legos, B. Mookerjee, Jean‐Jacques Grob - Annals of Oncology 2017 被引用: 652

  23. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

    著者: Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty - The Lancet Oncology 2018 被引用: 586

  24. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    著者: Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, Ana Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandalà, L. Thomas, Lev Demidov, Claus Garbe, David Hogg, Gabriella Liszkay, Paola Queirolo, Ernesto Wasserman, James Ford, Marine Weill, L. Andres Sirulnik, Valentine Jehl, Viviana Bozón, Georgina V. Long, Keith T. Flaherty - The Lancet Oncology 2017 被引用: 491